Ignite Creation Date:
2025-12-24 @ 6:31 PM
Ignite Modification Date:
2025-12-25 @ 4:01 PM
Study NCT ID:
NCT02325557
Status:
COMPLETED
Last Update Posted:
2024-04-02
First Post:
2014-12-22
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor:
Advaxis, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-04
Start Date Type:
ACTUAL
Primary Completion Date:
2019-08-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-01-22
Completion Date Type:
ACTUAL
First Submit Date:
2014-12-22
First Submit QC Date:
None
Study First Post Date:
2014-12-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-02-22
Results First Submit QC Date:
None
Results First Post Date:
2024-02-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-07
Last Update Post Date:
2024-04-02
Last Update Post Date Type:
ACTUAL